register

News & Trends - Biotechnology

Aussie biotech Prescient announces development programs for next-generation CAR-T therapy

Health Industry Hub | January 20, 2021 |

Biotech News: Prescient Therapeutics, an Australian biotechnology company developing personalised medicines for cancer, announced its internal development programs for OmniCAR, a next-generation CAR-T therapy platform.

The company has a research partnership with the Melbourne-based Peter MacCallum Cancer Centre to produce technology that can complement CAR T treatments.

OmniCAR is a universal immune receptor technology platform that offers a number of potential benefits over existing CAR-T therapies, including control, safety, flexibility and efficacy. With a platform technology with such a broad range of potential applications, it was important for Prescient to strategically select indications and applications for internal development that struck a balance between market opportunity, technical complexity and product differentiation.

Prescient is pleased to announce three internal programs representing significant market opportunities, where current-generation CAR-T have faced challenges, but where the unique capabilities of OmniCAR may present distinct advantages.

The development programs are:

  1. OmniCAR CD33 and CLL-1 for Acute Myeloid Leukemia (AML);
  2. OmniCAR Her2 for Her2+ solid tumours including breast, ovarian and gastric cancers; and
  3. OmniCAR Her2 and EGFRviii for glioblastoma multiforme (GBM).

Prescient Therapeutics Managing Director and CEO Steven Yatomi-Clarke said, “We are delighted to select these internal programs as truly differentiated, next-generation CAR-T products for Prescient. Each of the programs represent a tremendous market opportunity.”

“Furthermore, Prescient will continue to seek collaborations with external parties on additional opportunities where OmniCAR can create additional next-generation CAR therapies with partners.”

The application of OmniCAR technology in these cancers is expected to have benefits over conventional CAR T therapy, including: titration for improved safety; the ability to switch antigen targeting; co-arming CAR-T against multiple antigens simultaneously; persistent dosing and tumour microenvironment enhancements to improve efficacy.

The vigorous development program will move OmniCAR towards clinical programs while demonstrating the unique features of the technology in treating patients, which will add tremendous value to the OmniCAR platform.


Digital & Innovation

Reimagining remote care with Australia’s first virtual hospital

Reimagining remote care with Australia’s first virtual hospital

Health Industry Hub | April 24, 2025 |

Australia’s first virtual hospital is taking on a new role as a national testbed for advancing the future of patient-facing […]

More


News & Trends - MedTech & Diagnostics

Health Minister and Opposition face off at the National Press Club

Health Minister and Opposition face off at the National Press Club

Health Industry Hub | April 24, 2025 |

In a blistering showdown at the National Press Club, Federal Health Minister, Mark Butler, and his Opposition counterpart Senator Anne […]

More


News & Trends - Pharmaceuticals

GSK nabs label expansion for RSV vaccine

GSK nabs label expansion for RSV vaccine

Health Industry Hub | April 24, 2025 |

Coinciding with World Immunisation Week (24-30 April), GSK has secured TGA approval for its respiratory syncytial virus (RSV) vaccine, marking […]

More


News & Trends - MedTech & Diagnostics

Low-value imaging linked to high human cost

Low-value imaging linked to high human cost

Health Industry Hub | April 23, 2025 |

Imagining has become a cornerstone of modern medicine, for their ability to detect cancers, guide surgeries, and uncover internal injuries […]

More


This content is copyright protected. Please subscribe to gain access.